Morin C, Bairati I, Bouchard C, Fortier M, Roy M, Moore L, Meisels A
Departments of Pathology, Social and Preventive Medicine, and of Gynecology and Obstetrics, Laval University, Quebec, Canada.
J Reprod Med. 2001 Sep;46(9):799-805.
To assess strategies using repeated conventional Pap smear and human papillomavirus (HPV) DNA testing, alone or in combination, for identifying women with concomitant cervical intraepithelial neoplasia 2 and 3 (CIN 2/3) in women with atypical squamous cells of undetermined significance (ASCUS) in their Pap smears.
A total of 360 women cytologically diagnosed with ASCUS were referred for colposcopy and underwent a repeat Pap smear, a biopsy when necessary and HPV testing using three different modes of detection of high-oncogenic-risk HPV types: 1, first-generation Hybrid Capture test (HC-1) (Digene Diagnostics, Gaithersburg, Maryland); 2, second-generation Hybrid Capture test (HC-2); and 3, polymerase chain reaction (PCR).
Nineteen patients (5.3%) had histologic CIN 2/3. The sensitivity and specificity of the repeat Pap smear alone for the detection of CIN 2/3 were 73.7% and 62.9%, respectively, when referring all women with a repeat Pap smear using an ASCUS-positive threshold. The proportion of women referred for colposcopy was 39.0%. When HPV testing for high risk was used for identification of women with histologic CIN 2/3, sensitivity and specificity were, respectively, 68.4% and 85.9% for HC-1, 89.5% and 73.9% for HC-2 and 89.5% and 59.0% for PCR. The rate of referral for colposcopy of these three modes of HPV testing was 16.9%, 29.4% and 44.0%, respectively. The sensitivity and specificity for identification of women with concomitant CIN 2/3 using a combination of repeat cytology showing a low grade squamous intraepithelial lesion or high grade squamous intraepithelial lesion and/or a test positive for high-oncogenic-risk HPV group were, respectively, 94.7% and 73.2% when used in combination with HC-2. The referral rate of women for colposcopy of this combined strategy was 30.4%.
As compared to the strategy using abnormal repeat Pap smear alone, those using high-risk HPV testing with Hybrid Capture showed statistically significantly higher specificities and lower proportions of women with ASCUS referred for colposcopy. In particular, a promising strategy would be to refer for colposcopy only women with repeat Pap smears showing squamous intraepithelial lesion and/or those positive for high-risk HPV detected by Hybrid Capture testing.
评估单独或联合使用重复传统巴氏涂片和人乳头瘤病毒(HPV)DNA检测的策略,以识别巴氏涂片显示意义不明确的非典型鳞状细胞(ASCUS)的女性中合并宫颈上皮内瘤变2级和3级(CIN 2/3)的女性。
总共360名经细胞学诊断为ASCUS的女性被转诊进行阴道镜检查,并接受重复巴氏涂片检查,必要时进行活检,以及使用三种不同的高致癌风险HPV类型检测模式进行HPV检测:1. 第一代杂交捕获试验(HC-1)(Digene诊断公司,马里兰州盖瑟斯堡);2. 第二代杂交捕获试验(HC-2);3. 聚合酶链反应(PCR)。
19名患者(5.3%)患有组织学CIN 2/3。当以ASCUS阳性阈值对所有进行重复巴氏涂片检查的女性进行评估时,单独重复巴氏涂片检测CIN 2/3的敏感性和特异性分别为73.7%和62.9%。转诊进行阴道镜检查的女性比例为39.0%。当使用高危HPV检测来识别组织学CIN 2/3的女性时,HC-1的敏感性和特异性分别为68.4%和85.9%,HC-2的敏感性和特异性分别为89.5%和73.9%,PCR的敏感性和特异性分别为89.5%和59.0%。这三种HPV检测模式的阴道镜检查转诊率分别为16.9%、29.4%和44.0%。使用显示低级别鳞状上皮内病变或高级别鳞状上皮内病变的重复细胞学检查和/或高致癌风险HPV组检测呈阳性的联合检测方法识别合并CIN 2/3的女性时,与HC-2联合使用时的敏感性和特异性分别为94.7%和73.2%。这种联合策略的女性阴道镜检查转诊率为30.4%。
与单独使用异常重复巴氏涂片的策略相比,使用杂交捕获法进行高危HPV检测的策略在统计学上具有显著更高的特异性,且ASCUS女性转诊进行阴道镜检查的比例更低。特别是,一种有前景的策略是仅将重复巴氏涂片显示鳞状上皮内病变和/或杂交捕获检测发现高危HPV阳性的女性转诊进行阴道镜检查。